Cancer Research · 2022 · 68 citations · 50 references
MedicineCancer BiologyOncologyCancer ImmunologyDna RepairMolecular OncologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmune CheckpointsSynthetic LethalityImmune Checkpoint Inhibitor TherapyImmune Checkpoint ResistanceOlaparib TherapyParp InhibitionParp Inhibitor ResistanceParp Inhibitor SensitivityResistance To Checkpoint InhibitorsResistance To Immune Checkpoint Inhibition
BRCA1-mediated homologous recombination is an important DNA repair mechanism that is the target of FDA-approved PARP inhibitors, yet details of BRCA1-mediated functions remain to be fully elucidated. Similarly, immune checkpoint molecules are targets of FDA-approved cancer immunotherapies, but the biological and mechanistic consequences of their application are incompletely understood. We show here that the immune checkpoint molecule PD-L1 regulates homologous recombination in cancer cells by promoting BRCA1 nuclear foci formation and DNA end resection. Genetic depletion of tumor PD-L1 reduced homologous recombination, increased nonhomologous end joining, and elicited synthetic lethality to PARP inhibitors olaparib and talazoparib in vitro in some, but not all, BRCA1 wild-type tumor cells. In vivo, genetic depletion of tumor PD-L1 rendered olaparib-resistant tumors sensitive to olaparib. In contrast, anti-PD-L1 immune checkpoint blockade neither enhanced olaparib synthetic lethality nor improved its efficacy in vitro or in wild-type mice. Tumor PD-L1 did not alter expression of BRCA1 or its cofactor BARD1 but instead coimmunoprecipitated with BARD1 and increased BRCA1 nuclear accumulation. Tumor PD-L1 depletion enhanced tumor CCL5 expression and TANK-binding kinase 1 activation in vitro, similar to known immune-potentiating effects of PARP inhibitors. Collectively, these data define immune-dependent and immune-independent effects of PARP inhibitor treatment and genetic tumor PD-L1 depletion. Moreover, they implicate a tumor cell-intrinsic, immune checkpoint-independent function of PD-L1 in cancer cell BRCA1-mediated DNA damage repair with translational potential, including as a treatment response biomarker. SIGNIFICANCE: PD-L1 upregulates BRCA1-mediated homologous recombination, and PD-L1-deficient tumors exhibit BRCAness by manifesting synthetic lethality in response to PARP inhibitors, revealing an exploitable therapeutic vulnerability and a candidate treatment response biomarker. See related commentary by Hanks, p. 2069.
50
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
Talia Golan, Pascal Hammel, Michele Reni et al. · New England Journal of Medicine · 2019 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +17
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu et al. · New England Journal of Medicine · 2015 · 2.2K citations · Full text
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang, Michael A. Postow, Robert J. Orlowski et al. · Nature · 2017 · 1.7K citations · Full text
Life Sciences, Immunology, Oncology +16
XRCC3 promotes homology-directed repair of DNA damage in mammalian cells
Andrew J. Pierce, Roger D. Johnson, L.H. Thompson et al. · Genes & Development · 1999 · 1.4K citations · Full text